Glioma,MGMT,Methylation,Prognosis ,"/> <p class="MsoNormal" style="text-align:justify;"> Methylation of MGMT promoter in glioma and its clinical significance 

Chinese Clinical Oncology ›› 2019, Vol. 24 ›› Issue (2): 153-157.

Previous Articles     Next Articles

Methylation of MGMT promoter in glioma and its clinical significance 

  

  1. Department of Neurosurgery， the First Affiliated Hospital of Henan University of Science and Technology， Luoyang 471000， China

  • Received:2018-08-29 Revised:2018-11-22 Online:2019-02-28 Published:2019-03-18

PDF (PC)

677

Abstract:

Objective  To analyze the methylation status of promoter of O6-methylguanine-DNA methyltransferase （MGMT） gene and its relationship with clinicopathological features and prognosis of glioma. Methods The methylation level of MGMT was detected by methylation specific polymerase chain reaction （MSP） in 70 glioma tissues and 14 normal brain tissues of non-tumor patients who underwent surgical treatment from January 2012 to June 2013. The relationship between MGMT methylation and clinicopathological features was analyzed. Overalll survival （OS） of patients with high and low grade glioma with different MGMT methylation status was compared. Cox proportional regression model was used to analyze the factors affecting OS in low-grade glioma patients. Results Of 70 glioma patients， 48 （68.6％） had MGMT promoter methylation， while only 2 （14.3％） had MGMT methylation in normal brain tissues （P＜0.05）. MGMT methylation was not correlated with age， sex， tumor type， KPS score， p53 and Ki-67 expression （P＞0.05）， but with pathological grade （P＜0.05）. The median OS of MGMT methylated glioma patients was 30 months， significantly longer than that of non-methylated glioma patients for 11 months （P＜0.05）. Univariate analysis showed that WHO pathological grade， alkylating agent chemotherapy and MGMT methylation were associated with OS in low-grade glioma patients （P＜0.05）. Multivariate analysis showed that WHO grade Ⅱ， non-alkylation chemotherapy and MGMT non-methylation were independent risk factors for OS in low-grade glioma patients （P＜0.05）. Conclusion MGMT methylation is related to the occurrence and development of glioma. It has certain value in judging the malignancy of glioma， evaluating prognosis and guiding clinical treatment.

Key words:

Glioma')">"> Glioma, MGMT, Methylation, Prognosis

CLC Number: 

  • R739.41
[1] NIU Hong, TIAN Tongde, TANG Jingwen, YUE Guangxing, LI Huahua, FAN Yixiao, ZHOU Haoben..

Targeted regulation of MAP3K9 expression by microRNA-148a-3p and its effect on proliferation and apoptosis of gastric cancer cells [J]. Chinese Clinical Oncology, 2019, 24(2): 108-112.

[2] CHENG Chunlai, DING Wen, CHE Yuan.. Experimental study of YKL-40 regulating cisplatin resistance in endometrial cancer [J]. Chinese Clinical Oncology, 2019, 24(2): 113-118.
[3] YANG Caidi, WANG Lijuan, ZENG Dinghua, ZHU Jianmei..

MiR-122 induces apoptosis of glioma cells by targeting RUNX2 [J]. Chinese Clinical Oncology, 2019, 24(2): 124-128.

[4] Department of Gastroenterology, Central Hospital Affiliated to Shenyang Medical College, Shenyang , China.

Effect of mithramycin on cell cycle and apoptosis of gastric cancer cells and its possible mechanism [J]. Chinese Clinical Oncology, 2019, 24(2): 133-136.

[5] WEI Lei, LI Zixiong, QIN Shuqui, LIU Xiufeng..

The meta-analysis of clinical efficacy of gemcitabine monotherapy and gemcitabine combined with nab-paclitaxel for East Asian patients with advanced stage pancreatic adenocarcinoma [J]. Chinese Clinical Oncology, 2019, 24(2): 137-144.

[6] ZHANG Ning, LU Chuangxin, WU Sen, HE Yi, WEI Li. .

Expression and clinical significance of miRNA-138-5p in non-small cell lung cancer [J]. Chinese Clinical Oncology, 2019, 24(2): 149-152.

[7] LI Zhenmiao, SONG Bo, ZHAO Yi..

Clinical observation on the long-term survival and immune function of breast-conserving surgery with X-ray intensity-modulated radiotherapy [J]. Chinese Clinical Oncology, 2019, 24(2): 158-162.

[8] LIU Zhengcao, CHEN Qingqing, YUAN Guangda, ZHU Jiahao, WU Jinchang, JI Shengjun..

Value of neutrophil／lymphocyte ratio in evaluating the prognosis of senile esophageal carcinoma after radiotherapy [J]. Chinese Clinical Oncology, 2019, 24(2): 167-170.

[9] WANG Ying, ZHANG Tongmei, DONG Yujie, LI Baolan..

Clinical analysis of 24 cases of thymic squamous cell carcinoma [J]. Chinese Clinical Oncology, 2019, 24(2): 171-174.

[10] . [J]. Chinese Clinical Oncology, 2019, 24(2): 188-189.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Chinese Clinical Oncology, 2009, 14(1): 47 .
[2] . [J]. Chinese Clinical Oncology, 2009, 14(1): 68 .
[3] . [J]. Chinese Clinical Oncology, 2009, 14(1): 51 .
[4] . [J]. Chinese Clinical Oncology, 2009, 14(2): 176 .
[5]

. [J]. Chinese Clinical Oncology, 2009, 14(2): 118 .
[6] . [J]. Chinese Clinical Oncology, 2009, 14(2): 157 .
[7] . [J]. Chinese Clinical Oncology, 2009, 14(2): 166 .
[8] . [J]. Chinese Clinical Oncology, 2009, 14(2): 162 .
[9] . [J]. Chinese Clinical Oncology, 2009, 14(2): 170 .
[10] . [J]. Chinese Clinical Oncology, 2009, 14(3): 207 .
Copyright © Chinese Clinical Oncology, All Rights Reserved.
Tel: 025-84400143 85862116　E-mail: lczlx@csco.org.cn; lczlx@vip.163.com
Powered by Beijing Magtech Co. Ltd